Clinical trial
Harvard Atherosclerosis Reversibility Project (HARP)
NCT00000461 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00000461 |
|---|---|
| Title | Harvard Atherosclerosis Reversibility Project (HARP) |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial Ischemia |
| Intervention type | Drug |
| Interventions | pravastatin, niacin, cholestyramine, gemfibrozil, fatty acids, omega-3 |
| Start date | Dec 1, 1986 |
| Completion | Nov 1, 1992 |
| First posted | Oct 28, 1999 |
| Last update posted | Mar 16, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: